Imunon Is A Fully Integratedclinical Stagebiotechnology Company Focused On Advancing A Portfolio Of Innovativetreatments That Harness Thebody S Natural Mechanisms To Generatesafeeffectiveand Durableresponses Across A Broad Array Of Human Diseases Imunon Has Two Platform Technologiesour Theraplasaplatform For Thedevelopment Of Immunotherapies And Other Anti Cancer Nucleic Acid Based Therapies And Our Placcineplatform For Thedevelopment Of Nucleic Acid Vaccines For Infectious Diseases And Cancerthecompany S Lead Clinical Programgen 1Is A Dna Based Immunotherapy For Thelocalized Treatment Of Advanced Ovarian Cancer Currently In Phaseii Developmentgen 1 Works By Instructing Thebody To Producesafeand Durablelevels Of Powerful Cancer Fighting Moleculessuch As Interleukin 12Il 12And Interferon Gammaifn I At Thetumor Sitein Additionweareconducting Preclinical Proof Of Concept Studies On A Nucleic Acid Vaccinecandidatetargeting Sars Cov 2 Virus In Order To Validateour Placcineplatformimunon S Platform Technologies Arebased On Thedelivery Of Nucleic Acids With Novel Synthetic Delivery Systems That Areindependent Of Viral Vectors Or Deviceswewill Continueto Leveragetheseplatforms And To Advancethetechnological Frontier Of Plasmid Dna To Better Servepatients With Difficult To Treat Conditions
